» Articles » PMID: 18278532

Sacral Nerve Stimulation is More Effective Than Optimal Medical Therapy for Severe Fecal Incontinence: a Randomized, Controlled Study

Overview
Specialty Gastroenterology
Date 2008 Feb 19
PMID 18278532
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: This randomized study was designed to compare the effect of sacral neuromodulation with optimal medical therapy in patients with severe fecal incontinence.

Methods: Patients (aged 39-86 years) with severe fecal incontinence were randomized to have sacral nerve stimulation (SNS group; n = 60) or best supportive therapy (control; n = 60), which consisted of pelvic floor exercises, bulking agent, and dietary manipulation. Full assessment included endoanal ultrasound, anorectal physiology, two-week bowel diary, and fecal incontinence quality of life index. The follow-up duration was 12 months.

Results: The sacral nerve stimulation group was similar to the control group with regard to gender (F:M = 11:1 vs. 14:1) and age (mean, 63.9 vs. 63 years). The incidence of a defect of < or = 120 degrees of the external anal sphincter and pudendal neuropathy was similar between the groups. Trial screening improved incontinent episodes by more than 50 percent in 54 patients (90 percent). Full-stage sacral nerve stimulation was performed in 53 of these 54 "successful" patients. There were no septic complications. With sacral nerve stimulation, mean incontinent episodes per week decreased from 9.5 to 3.1 (P < 0.0001) and mean incontinent days per week from 3.3 to 1 (P < 0.0001). Perfect continence was accomplished in 25 patients (47.2 percent). In the sacral nerve stimulation group, there was a significant (P < 0.0001) improvement in fecal incontinence quality of life index in all four domains. By contrast, there was no significant improvement in fecal continence and the fecal incontinence quality of life scores in the control group.

Conclusions: Sacral neuromodulation significantly improved the outcome in patients with severe fecal incontinence compared with the control group undergoing optimal medical therapy.

Citing Articles

Electroceuticals for Neurogastroenterology and Motility Disorders.

Jiang Y, Soffer E Curr Gastroenterol Rep. 2023; 25(4):91-97.

PMID: 36867326 PMC: 10102147. DOI: 10.1007/s11894-023-00866-9.


Anorectal manometry findings in relation with long-term functional outcomes of the patients operated on for Hirschsprung's disease compared to the reference-based population.

Trinh T, Nguyen N, Lam K, Pham T, Vu N, Truong L Pediatr Surg Int. 2023; 39(1):131.

PMID: 36800080 DOI: 10.1007/s00383-023-05402-4.


Guideline for the diagnosis and treatment of Faecal Incontinence-A UEG/ESCP/ESNM/ESPCG collaboration.

Assmann S, Keszthelyi D, Kleijnen J, Anastasiou F, Bradshaw E, Brannigan A United European Gastroenterol J. 2022; 10(3):251-286.

PMID: 35303758 PMC: 9004250. DOI: 10.1002/ueg2.12213.


The Efficacy of Biofeedback Treatment in Patients with Fecal Incontinence.

Ozturk O, Ozin Y, Bacaksiz F, Tenlik I, Ari D, Gokbulut V Turk J Gastroenterol. 2021; 32(7):567-574.

PMID: 34464319 PMC: 8975453. DOI: 10.5152/tjg.2021.20430.


Comparative effectiveness of biofeedback and injectable bulking agents for treatment of fecal incontinence: Design and methods.

Bharucha A, Gantz M, Rao S, Lowry A, Chua H, Karunaratne T Contemp Clin Trials. 2021; 107:106464.

PMID: 34139357 PMC: 8429255. DOI: 10.1016/j.cct.2021.106464.